Noxopharm (NOX:ASX) announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.
Gisela Mautner, MD, PhD, Noxopharm CMO, said, “The IND approval, based on pre-clinical and clinical data presented to the FDA, is validation of the clinical potential of Veyonda®. In addition, Veyonda® has met the very high standard set by the FDA for being a safe and well-tolerated drug.”
For more information, download the attached PDF.
Download this document